title: Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children.
abstract: OBJECTIVE
  To determine the value of indium-111-antimyosin ((111)In-AM) scintigraphy in the early detection of myocardial damage in children treated with doxorubicin.
  
  
  METHODS
  Twelve planar scintigrams were made of eight patients (seven children and one young adult; mean age, 12 years). Three scans were obtained before doxorubicin therapy in three patients, and nine scans were obtained during doxorubicin therapy in seven patients. The heart-to-lung ratio (HLR) was calculated. Left ventricular function was assessed by echocardiography before and during therapy by measuring the fractional shortening (FS).
  
  
  RESULTS
  The HLR of the three baseline scans was below 1.5, within the normal range for adults. Six of the seven patients whose scans were obtained during chemotherapy had abnormal HLR values (> 1.5). One patient had severe myocyte damage and showed an early increase in the HLR (2.3) after a cumulative doxorubicin dose of 150 mg/m(2). The FS measured by echocardiography was normal throughout therapy, and the final cumulative dose of doxorubicin was 450 mg/m(2). This patient developed fatal clinical heart failure 3 months after completion of chemotherapy. In one patient, who was pretreated with the cardioprotective agent dexrazoxane, the HLR remained within normal limits during therapy.
  
  
  CONCLUSIONS
  (111)In-AM scintigraphy seems to be suitable to detect early myocardial damage after a cumulative doxorubicin dose of 150 mg/m(2 )in children and may be useful for identifying children who are at increased risk of developing cardiac sequelae.
authors.affiliation: Department of Pediatrics, Academic Medical Center, Emma Children's Hospital, University of Amsterdam, The Netherlands. l.c.kremer@amc.uva.nl
authors.forename: L C
authors.initials: LC
authors.lastname: Kremer
authors.forename: M M
authors.initials: MM
authors.lastname: Tiel-van Buul
authors.forename: M C
authors.initials: MC
authors.lastname: Ubbink
authors.forename: M
authors.initials: M
authors.lastname: Offringa
authors.forename: J
authors.initials: J
authors.lastname: Ottenkamp
authors.forename: R V
authors.initials: RV
authors.lastname: Olmos
authors.forename: P A
authors.initials: PA
authors.lastname: Voûte
mesh_terms: D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004317:Doxorubicin / Q000009:adverse effects* / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging* / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D007205:Indium Radioisotopes; D007223:Infant; D008297:Male; D009218:Myosins / Q000276:immunology*; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D010865:Pilot Projects; D016719:Radioimmunodetection; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology
chemical_list: D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007205:Indium Radioisotopes; D004317:Doxorubicin; D009218:Myosins